Truvian announced on Wednesday that it has closed a $105 million Series C financing round, bringing the total amount the company has raised to date to more than $150 million.
Truvian Sciences, a San Diego startup that’s developing a benchtop blood testing machine to bring rapid, point-of-care health screening to local pharmacies, medical clinics and corporate wellness centers, has raised $105 million in a third round of venture capital funding
With its eyes set on securing an FDA clearance for its automated bench top blood testing system, Truvian Sciences has raised more than $105 million in new financing for the final steps of its development. The series C round will also help scale up the company’s commercialization teams in preparation for launch—alongside several new appointments to its C-suite and board of directors
The benchtop system is designed to combine chemistries, immunoassays and hematology assays in one device, with the combination of such testing modalities allowing clinics to perform all standard blood tests during a routine check-up on-site, saving cost and time